MD Anderson | Strategic Alliance Partners

Latest from MD Anderson

Atezolizumab/Bevacizumab Lays the Groundwork for Optimal Sequencing in HCC

November 25, 2020

Milind Javle, MD, provides insight into the current treatment paradigm of advanced HCC and the potential influence ongoing research regarding biomarkers of response and novel combinations could have on the field.

Mesa and Ulmer Measure Methods for JAK Inhibitor Optimization in Myelofibrosis

November 19, 2020

In our exclusive interview, Dr. Mesa and Dr. Ulmer discuss the current roles of ruxolitinib and fedratinib in myelofibrosis, current guidance for JAK inhibitor dosing, the utility of re-exposure to JAK inhibitors, and clinical trial options.

Charting the Course for Patients With High-Risk Colon Cancer: 3 Months Versus 6 Months

November 19, 2020

In 5 years, it is estimated that approximately 20% of patients with stage II disease and 35% with stage III disease will experience disease recurrence. These estimates highlight the need to pursue progress in adjuvant systemic therapy in order to decrease recurrence rates and improve survival.

Tripathy Talks Genomics, Targeted Treatments, and Smart Trial Designs in Breast Cancer

November 06, 2020

In our exclusive interview, Debu Tripathy, MD, considers the biological and long-term outcome variability of HR-positive, HER2-negative breast cancer and details the research that is being done to develop personalized treatment approaches.